Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George W Rutherford

Showing results (1-10 of 164) with videos related to

Pageof 17
Sort By:
BMJ (Clinical Research Ed.)|December 6, 2011
Antiretroviral therapy and the prevention of sexually transmitted HIV infectionGeorge W Rutherford
Lancet (London, England)|July 29, 2008
Condoms in concentrated and generalised HIV epidemicsGeorge W Rutherford
Evidence-Based Medicine|November 18, 2016
Early initiation of antiretroviral therapy prevents HIV transmission to seronegative sexual partnersGeorge W Rutherford, Andrew Anglemyer
Collegium Antropologicum|May 19, 2007
The epidemiology of HIV and AIDS in the worldAliya Bokazhanova, George W Rutherford
The New England Journal of Medicine|September 8, 2020
Facial Masking for Covid-19 - Potential for "Variolation" as We Await a VaccineMonica Gandhi, George W Rutherford
Evidence-Based Medicine|November 15, 2017
Supplementary antimicrobials for patients with HIV and <100 CD4 cells/µL are associated with improved survivalGeorge W Rutherford, Elvin Geng
Evidence-Based Medicine|December 15, 2015
Initiating antiretroviral therapy in HIV-infected patients with >500 CD4 cells/µL provides more benefit than delaying treatmentGeorge W Rutherford, Andrew Anglemyer
The New England Journal of Medicine|October 23, 2020
Facial Masking for Covid-19. ReplyMonica Gandhi, George W Rutherford
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2020
Coinfection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and Influenza: An Evolving PuzzleSara Covin, George W Rutherford
The Lancet. HIV|February 4, 2017
Is 90-90-90 achievable?George W Rutherford, Andrew Anglemyer
Pageof 17

Showing results (1-10 of 164) with videos related to

Sort By:
Pageof 17
BMJ (Clinical Research Ed.)|December 6, 2011
Antiretroviral therapy and the prevention of sexually transmitted HIV infectionGeorge W Rutherford
Lancet (London, England)|July 29, 2008
Condoms in concentrated and generalised HIV epidemicsGeorge W Rutherford
Evidence-Based Medicine|November 18, 2016
Early initiation of antiretroviral therapy prevents HIV transmission to seronegative sexual partnersGeorge W Rutherford, Andrew Anglemyer
Collegium Antropologicum|May 19, 2007
The epidemiology of HIV and AIDS in the worldAliya Bokazhanova, George W Rutherford
The New England Journal of Medicine|September 8, 2020
Facial Masking for Covid-19 - Potential for "Variolation" as We Await a VaccineMonica Gandhi, George W Rutherford
Evidence-Based Medicine|November 15, 2017
Supplementary antimicrobials for patients with HIV and <100 CD4 cells/µL are associated with improved survivalGeorge W Rutherford, Elvin Geng
Evidence-Based Medicine|December 15, 2015
Initiating antiretroviral therapy in HIV-infected patients with >500 CD4 cells/µL provides more benefit than delaying treatmentGeorge W Rutherford, Andrew Anglemyer
The New England Journal of Medicine|October 23, 2020
Facial Masking for Covid-19. ReplyMonica Gandhi, George W Rutherford
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2020
Coinfection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and Influenza: An Evolving PuzzleSara Covin, George W Rutherford
The Lancet. HIV|February 4, 2017
Is 90-90-90 achievable?George W Rutherford, Andrew Anglemyer
Pageof 17